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Abstract  
We would like this piece to be considered for publication as an editorial and have therefore not 
provided an abstract. We are of course happy to be advised otherwise. 
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Introduction 
Mobile health technology, also known as mHealth, makes potentially empowering health 
interventions more widely available. One area of focus across health conditions has been in 
relation to the remote measurement of changes in wellbeing using mobile technology 
(Simblett et al., 2018). Remote monitoring systems have been developed and tested for 
people with experiences of psychosis (Marzano et al., 2015; O’Hanlon et al., 2016) where the 
anticipation and prevention of relapse has long been a treatment and policy goal and, while it 
is too early to draw firm conclusions on effectiveness, acceptability and feasibility have been 
found to be consistently high (Naslund, Marsch, McHugo, & Bartels, 2015). While we have 
had evidence for some time that it is possible to identify early signs of psychosis, acting upon 
those signs in a way which is supportive and avoids the need for coercive treatment decisions 
is harder to achieve (Morriss, Vinjamuri, Faizal, Bolton, & McCarthy, 2013). It is also 
established that early signs are accompanied by a fear of relapse (Herz & Melville, 1980) and 
that fear of relapse is a predictor of relapse which may block help seeking (Gumley et al., 
2015). 
Mobile technology provides an opportunity to overcome some of the barriers to 
implementation of early signs work through active (e.g. completion of self-report assessments) 
and sometimes passive monitoring (e.g. routinely gathered location or phone usage data) in 
real time and in people’s normal environments. This approach, which can also be 
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characterised as ecological momentary assessment (EMA), has the potential to reduce the 
type of recall bias associated with retrospectively gathering data (Shiffman, Stone, & Hufford, 
2008) and is increasingly being applied in psychosis research and clinical settings (Bell, Lim, 
Rossell, & Thomas, 2017).  Such routine monitoring also provides data, which might support 
shared decision making and reduce the risk of practitioners acting conservatively when faced 
with ambiguity and uncertainty. 
Monitoring mental health is, however, not a neutral process – measuring things generally has 
the potential to effect the person being measured both positively and negatively (Miles et al., 
2018). There is a risk that in our enthusiasm for the potential benefits of mHealth psychosis 
that we are failing to properly assess, and learn from, potential adverse effects. There have 
been warnings against the risk of seeing digital interventions in mental health as a panacea 
for long standing and complex problems (Wykes & Brown, 2016). Interventions may also be 
causing harm through overselling their benefits (Wykes, 2019) and as a result of being 
insufficiently sensitive to the often complex needs of people affected by serious mental health 
problems (Lipczynska, 2016). An increased focus on the  duality of costs and benefits in 
digital interventions has been commented on in this journal (Guha, 2017) and the need to 
more rigorously review both costs and benefits of digital interventions for mental health has 
been highlighted elsewhere (Armontrout, Torous, Fisher, Drogin, & Gutheil, 2016; Naeem et 
al., 2015; Rozental et al., 2014; Torous, Nicholas, Larsen, Firth, & Christensen, 2018). If we 
believe that such interventions have the potential to be efficacious then we must also be 
prepared for the possibility that effects may also be negative (Rozental et al., 2014).  Fully 
informed decisions on the future development or use of mHealth for psychosis interventions 
should be based on having detailed information available on all relative costs and benefits so 
it is telling that references to safety reporting and adverse events are rare in mHealth for 
psychosis literature.  
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Adverse events and possible proxies in mHealth for psychosis literature 
Bell et al. (2017) systematically reviewed nine studies of Ecological Momentary Assessment 
(EMA) and Interventions (Ben-Zeev et al., 2014; Ben-Zeev, Wang, et al., 2016; Depp et al., 
2010; Granholm, Ben-Zeev, Link, Bradshaw, & Holden, 2012; Pijnenborg et al., 2010; 
Sablier et al., 2012; Španiel, Vohlídka, Hrdlička, et al., 2008; Španiel, Vohlídka, Kožený, et 
al., 2008; Španiel et al., 2012). All featured some form of mHealth intervention designed to 
enhance care for people with experiences of psychosis. None of those studies described 
having undertaken adverse events monitoring. We identified nine further studies of mHealth 
for psychosis that either did not meet the inclusion criteria for the Bell et al. (2017) review or 
which were published subsequent to the review (Ainsworth et al., 2013; Barnett et al., 2018; 
Bucci et al., 2018; Eisner et al., in press; Kumar et al., 2018; Meyer et al., 2018; Niendam et 
al., 2018; Palmier-Claus et al., 2012; Španiel et al., 2018) Of these just one described adverse 
event monitoring and in that instance it was limited to the identification of serious adverse 
events1, with none noted over the twelve-month period of the Actissist trial (Bucci et al., 
2018). There was no indication of whether non-serious events were monitored or whether the 
relatedness of events to the digital intervention was assessed. 
Although there is little evidence of systematic within-study monitoring or reporting of 
adverse events and experiences, a number of studies do report relevant indices of 
acceptability and engagement. These are worthy of investigation as in some cases data may 
be indicative of adverse reactions to mHealth interventions. In a study of the FOCUS 
intervention, increased paranoia was cited as a reason for non-engagement by at least two 
people (Ben-Zeev, Scherer, et al., 2016). Palmier-Claus and colleagues (2012) included three 
questions to assess the safety of Clintouch monitoring but data were only reviewed once 
                                                          
1 Serious adverse events are defined by the UK Health Research Authority as including death, life threatening 
persistent or significant disability or incapacity, hospitalisation or prolongation of existing hospitalisation 
congenital anomaly or birth defects. 
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people had stopped using the system. Participants with the most acute symptoms were 
described as being the most ‘reactive’ to questions in the App although it was not possible to 
tell whether those reactions were positive or negative due to the wording of the questions. 
Ainsworth and colleagues (2013) compared text and App based delivery of the Clintouch 
questionnaire. At the end of the study participants were asked to rate how stressful and 
challenging they found the monitoring with some reporting mild negative effects. One 
participant also asked for text messaging to be terminated early because the questions led to 
unhelpful rumination. Meyer and colleagues asked 14 participants, who were using a 
combination of wearable and smartphone devices capturing rest and activity data, to complete 
a post study usability assessment (Meyer et al., 2018). Through this, concerns were expressed 
about the potential for the intervention to generate false alarms, discomfort from the wearable 
device and frustration at the repetitive nature of the integrated Clintouch symptom tracking 
component. In qualitative interviews, completed with people who had used the EXPRESS 
App to measure early signs and basic symptoms of psychosis, two people expressed concerns 
about feelings of paranoia and two mentioned concerns about potentially punitive service 
responses to their App data (Eisner et al., in press, 2019). 
A number of studies described relatively high levels of non-engagement and drop out, which 
may be an important opportunity to investigate adverse events or effects (Rozental et al., 
2014). It may be reasonable to hypothesise that in some instances negative experiences of 
interventions may have played a role in determining non-engagement. It is also notable that 
regardless of problems with engagement or wider implementation challenges, interventions 
are almost universally described as being acceptable and feasible. For example, in a small 
study of passive monitoring of behavioural indicators 20% of participants were described as 
being upset by the approach when acceptability was assessed at the end of the study (Ben-
Zeev, Wang, et al., 2016). Despite this feedback and the absence of routine adverse events 
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monitoring the intervention was still found to be feasible and acceptable. A recent review of 
engagement with Apps for people with diagnoses of depression, anxiety, schizophrenia or 
bipolar disorder found that no two studies, out of the 40 included, used the same means to 
assess engagement (Ng, Firth, Minen, & Torous, 2019). In addition, all 40 reported positive 
results for engagement or feasibility, including 15 studies where there was no objective 
measurement of engagement. Ng and colleagues (2019) proposed that the observed lack of 
consistency in describing, measuring and reporting engagement could be masking significant 
problems with usability and safety. 
In summary, this brief review of mHealth for psychosis literature suggests that the monitoring 
and reporting of adverse events or effects is largely neglected. While many of the included 
papers described small scale pilot or feasibility studies it is notable that just one described 
and reported adverse event monitoring procedures, and in that instance monitoring was 
limited to serious adverse events with no reference to the relatedness of events to the digital 
intervention (Bucci et al., 2018). Although studies tend to report levels of acceptability, 
usability and / or engagement these are poor surrogates for the direct and contemporaneous 
assessment of adverse or unwanted experiences.  Based on our experience, we believe that 
incorporating procedures to routinely identify and respond to adverse events enhances our 
understanding of how interventions are experienced. This improves our ability to modify 
interventions as required and to respond appropriately to safety issues as and when they arise. 
Learning from adverse events monitoring in the EMPOWER study 
One driver for improved adverse event monitoring could be regulatory. In the United States 
the Food and Drugs Administration has adopted a system based largely on demonstrating 
equivalence to already approved medical software (Armontrout et al., 2016). In the European 
Union member countries have introduced new systems to assess and regulate software as 
Medical Devices, based on European Commission Guidance on the Qualification and 
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Classification of standalone software as Medical Devices (MEDDEV 2.1/6). In the United 
Kingdom the competent authority is the Medicines and Healthcare products Regulatory 
Agency (MHRA) who registered the first App as a medical device in 2013 (McCarthy, 2013). 
It is our understanding that EMPOWER was the first mHealth intervention for mental health 
to be registered and regulated as a medical device by MHRA in 2017 (CI/2017/0039). 
Medical device regulation requires manufacturers and investigators to demonstrate 
compliance with the essential requirements of the European Directive. This includes legal 
requirements in relation to the assessment of performance and safety, including detailed 
monitoring and reporting of adverse events. New medical device regulations, which include 
clearer guidance on software as medical devices and its classification, will come into force in 
Europe in May 2020. This amendment is likely to bring increased regulatory and reporting 
requirements for researchers and developers. For example, it has been clarified that any 
software involved in decisions with a diagnostic or clinical therapeutic purpose will now be 
automatically categorised as at least Class 2a, which brings with it the need for assessment of 
conformity with regulations by third party notified bodies. 
EMPOWER (Early signs Monitoring to Prevent relapse in psychosis and prOmote Wellbeing, 
Engagement and Recovery, ISRCTN: 99559262) is a feasibility study of an mHealth 
intervention to enhance detection of Early Warning Signs of psychosis and prevent relapse. In 
our cluster randomised controlled trial, participants receiving care from community mental 
health services in Scotland and Australia are randomised to receive the EMPOWER 
intervention or treatment as usual. The intervention involves inviting participants to self-
monitor their wellbeing, including early signs of psychosis, for up to one year through a 
mobile phone App. Participants use the App, which integrates a degree of personalisation, for 
an initial twenty-eight day period to identify a personal baseline of their typical variation in 
wellbeing. Our stepped care approach includes the delivery of tailored messages in response 
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to lower threshold changes in scores against that baseline and the option to check in with App 
users and, or, community mental health staff, where there has been a higher threshold change. 
The algorithm, which reviews data and determines the best response, is registered and 
monitored as a Class 1 medical device with MHRA. While initial medical device registration 
was challenging the consequent heightening and refinement of routine adverse effects 
monitoring and reporting has usefully allowed us to respond quickly to feedback and adapt 
our intervention approach in light of end user experiences.  
Our adverse event procedures involve recording all untoward medical occurrences or clinical 
indications, their relatedness to the investigational medical device, their seriousness and 
intensity and whether or not the event was anticipated. We also separately monitor and report 
device deficiencies which are inadequacies of the medical device (the algorithm) with respect 
to its identity, quality, reliability, safety or performance. People using the EMPOWER App 
receive regular phone support from Peer Support Workers during which any negative 
experiences are reviewed. In addition, where a significant change in putative early signs is 
identified clinical staff contact participants to check in with their wellbeing and review any 
further actions required. Our approach is described in a detailed Standard Operating 
Procedure and all staff receive training in the identification and reporting of adverse events. 
There are regular opportunities to discuss and reflect on positive and negative experiences of 
people using the App. While team members are encouraged to take all adverse events 
seriously and to respond appropriately, they are also trained to see any negative effects as 
opportunities for learning about how we might improve end user experiences and to inform 
the development of the intervention.  
These processes have led to the identification of a number of important experiences that we 
have recorded as adverse events. While none have been related to the EMPOWER algorithm 
(i.e. the MHRA regulated medical device), a number of them are related to aspects of the 
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digital intervention as a whole. In total 41 people had the EMPOWER App installed between 
May and September 2018. Levels of usage have been variable and will be reported elsewhere 
in due course. In the period up to March 2019 we recorded 43 adverse events across the study 
as a whole. Of these, 27 were related to 17 people who were allocated to the EMPOWER arm 
of the study. Of this group of 17 participants we determined that the adverse event was 
related to the intervention in nine instances (accounting for the excess of adverse events in 
the EMPOWER arm), affecting seven people using the App, which will now be described. 
All but one of the nine adverse event that we deemed to be related to the EMPOWER App 
was categorised as non-serious. The one serious adverse event involved a hospital admission, 
which was described by the participant as being in part related to the installation of the 
EMPOWER App and an associated sense of feeling overwhelmed. The participant, who had 
not actually entered data into the App, then withdrew from the study after meeting with a 
member of the EMPOWER Team. 
On two occasions we recorded adverse events specifically related to the exposure to 
personalised items in the EMPOWER App. People using the App have the option to 
personalise a number of items to better fit with their own unique experiences. This function 
was included to allow for a more tailored experience and to improve the sensitivity and 
specificity of early signs to potential relapse. However, in these instances we found that 
memories of distressing and traumatic experiences of psychosis were triggered during routine 
monitoring. Our response in both instances was to edit the question set to remove 
personalised items and consequently both participants continued in the study. Personalised 
warning signs may have triggered intrusive memories of distressing psychosis, which can 
perhaps be understood in the context of previous research showing fear of recurrence 
predicted traumatic memories of psychosis (White & Gumley, 2009).   
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Two separate adverse event reports for the same participant related to increased feelings of 
paranoia as a result of being prompted to respond to questions at an inconvenient time. In 
both instances the participant was offered assurances by a peer support worker. This included 
reminding the participant of an inbuilt five-hour window to respond to questions, a feature 
which was included as a result of beta-testing feedback that suggested some people felt 
pressured by a limited response window. A heightened sense of paranoia and increased fear 
of recurrence were included in our protocol and medical device registration documents as 
anticipated risks of the intervention and heightened feelings of paranoia as a result of routine 
monitoring in psychosis have been reported elsewhere (Eisner et al., 2019; Terp, Jørgensen, 
Laursen, Mainz, & Bjørnes, 2018).  
One participant also alluded to increased fear of relapse as a result of the intervention, 
particularly on days when their mental health had taken a dip. Assurances were again given 
by a peer support worker and options for managing the App in the context of fluctuating 
mental health were discussed. The potential to generate fear, which is itself a strong predictor 
of relapse in psychosis (Gumley et al., 2015), through routine monitoring is well summed up 
by a participant in a recent qualitative examination of an mHealth for psychosis intervention: 
“Being notified of all the changes sometimes made me anxious. It made me wonder if the 
illness was maybe about to get out of control” (Terp et al., 2018, p. 8). 
A further intervention related adverse event early in the study was associated with a 
participant’s experience of self-monitoring being at odds with their usual coping strategy of 
‘burying things’ and ‘putting on a face.’ The participant was offered additional peer support 
and was encouraged to take a break from using the App but ultimately chose to withdraw 
from the study entirely. The potential for routine monitoring of signs and symptoms to 
encourage unhelpful rumination and pessimism for recovery has been described elsewhere 
(Ainsworth et al., 2013; Faurholt-Jepsen et al., 2015; Nicholas et al., 2010). This may suggest 
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the need to assess the extent to which self-monitoring might fit or be at odds with a 
participant’s current means of managing their wellbeing prior to using a digital intervention. 
In some instances, it may be advisable to conduct preparatory work to orientate potential 
users to the relative costs and benefits of monitoring wellbeing. In EMPOWER our 
experience is that these conversations can take place with a peer worker who can also support 
self-management. This need for heightened early monitoring and support is supported by the 
fact that in six of the nine intervention related adverse events in EMPOWER occurred within 
a month of the App being installed, and four of those within two weeks.  
Technical issues can also lead to problems with engagement and adverse effects for mHealth 
intervention users (see, for example, Kumar et al., 2018). Any such intervention is contingent 
upon an effective combination of software (the App) and hardware (the mobile device being 
used) and it can be extremely hard to anticipate all potential conflicts between a piece of 
software and the myriad of devices it may be deployed on (even where they use the same 
operating system). In one instance an unexplained conflict between the EMPOWER App and 
a specific handset led to notifications being sent in the night causing distress to a participant 
who felt compelled to respond. The participant subsequently withdrew from the study and 
following investigations it became clear that this problem was specific to one particular type 
of handset and as a result difficult to anticipate. There is also of course the possibility of 
misplacing research-provided handsets and one adverse event in the study related to distress 
and anxiety experienced as a result of a participant misplacing a study phone. They were 
offered reassurance and the possibility of a replacement handset. 
Conclusions 
A brief review of literature suggests that adverse event monitoring in mHealth for psychosis 
interventions is under developed with procedures being poorly reported. Heightened adverse 
event monitoring in the context of the EMPOWER study as a result of medical device 
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registration has highlighted relatively frequent adverse events, when compared with existing 
literature in the field, which can in some way be related to an aspect of the digital 
intervention. We have developed procedures and practices which have facilitated the timely 
identification of adverse events and we also encourage a culture whereby such events are 
seen as an opportunity to refine and improve the intervention. Whenever possible we adapt 
the intervention to better meet users’ needs.  
 
The philosophy underpinning EMPOWER is to enable and support individuals to lean in to 
their experiences of the “ebb and flow” of wellbeing. We do this by tailoring messages to 
enhance self-management, providing peer support with regular checking in to support and 
empower people using the App. Similarly, the culture in the team is important and we have 
actively supported staff to lean in to adverse effects that may occur in the context of the trial 
generally and app usage specifically. We believe this has produced a culture of learning that 
is enabling us to optimise the EMPOWER intervention for a future trial. 
One means of improving adverse event monitoring and reporting could be through an 
increased emphasis in reporting guidelines. It is therefore notable that the World Health 
Organisation checklist for reporting evidence and effectiveness in mHealth, also known as 
the mERA guidelines (Agarwal et al., 2016), makes no reference to either safety reporting or 
adverse events within their 16 item check list and that recommendations are similarly lacking 
from the CONSORT-EHEALTH reporting guidelines (Eysenbach & CONSORT-EHEALTH 
Group, 2011). Updating and expanding these, and other relevant standards could go a long 
way to improving reporting of mHealth for psychosis research which should ultimately 
improve the acceptability of interventions and minimise harm. 
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Adverse events in mHealth for psychosis should be anticipated and while as a research team 
we were obliged to introduce enhanced monitoring the effect of this has been 
overwhelmingly positive. With increased interest internationally in the regulation and 
monitoring of mHealth interventions it seems likely that the need for more mitigate the risk 
of detailed safety reporting will increase. However, regardless of the demands of regulators 
we encourage researchers to voluntarily adopt enhanced adverse event monitoring procedures, 
to apply them those throughout studies and to fully report their findings for the advancement 
of the field. While developing and implementing such procedures is time-consuming, 
ultimately they should improve experiences for end users and reduce inherent risks, while 
improving the acceptability and design of interventions. It might also unrealistically positive 
framing of mHealth for psychosis interventions from enthusiastic early adopters.  
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